Clinical Trials

JBCRG-17TR

Translational research for JBCRG-17(Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer)

Status
Study Closed

Objectives
Identification of a molecular marker to predict the therapeutic effect and marker for "Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17)"

Subjects
Among the patients who participated in the "Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17)"

1)Paraffin block 2)Frozen section 3)Plasma, Serum 4)Frozen whole blood

Endpoints

Trial Period
~November 2024

Lead Principal Investigator
JBCRG-17TR Principal Investigator : Yoshio Miki Japanese Foundation for Cancer Research Department of Genetic Diagonosis Cancer Institute Yosh

Target Sample Size
Patients who agreed to enter JBCRG-17 TR

Regimen

Source of Funding
Japan Breast Cancer Reserch Group, Japanese Foundation for Cancer Research, other

Conference Presentation

Articles and Publications

UMIN-ID
UMIN000009639

jRCT

Memo

COI Disclosure

Previous PageClinical TrialsNext Page